TSE:4503Pharmaceuticals
Astellas Pharma (TSE:4503) Is Up 13.9% After Raising FY2026 Guidance On XTANDI Momentum - Has The Bull Case Changed?
In early February 2026, Astellas Pharma Inc. raised its fiscal year ending March 31, 2026 guidance, now projecting revenue of ¥2.10 trillion and higher profits on both core and full-year bases, supported by stronger-than-expected earnings per share.
The company attributed these upgraded forecasts to robust global demand for its prostate cancer drug XTANDI and overactive bladder franchise, alongside beneficial foreign exchange effects that lifted expected profitability.
Next, we’ll examine...